PT - JOURNAL ARTICLE AU - Millat-Martinez, Pere AU - Gharbharan, Arvind AU - Alemany, Andrea AU - Rokx, Casper AU - Geurtsvankessel, Corine AU - Papageourgiou, Grigorios AU - van Geloven, Nan AU - Jordans, Carlijn AU - Groeneveld, Geert AU - Swaneveld, Francis AU - van der Schoot, Ellen AU - Corbacho-Monné, Marc AU - Ouchi, Dan AU - Ferreira, Francini Piccolo AU - Malchair, Pierre AU - Videla, Sebastian AU - García, Vanesa García AU - Ruiz-Comellas, Anna AU - Ramírez-Morros, Anna AU - Codina, Joana Rodríguez AU - Simon, Rosa Amado AU - Grifols, Joan-Ramon AU - Blanco, Julian AU - Blanco, Ignacio AU - Ara, Jordi AU - Bassat, Quique AU - Clotet, Bonaventura AU - Baro, Bàrbara AU - Troxel, Andrea AU - Zwaginga, Jaap Jan AU - Mitjà, Oriol AU - Rijnders, Bart AU - , AU - , TI - Convalescent plasma for outpatients with early COVID-19 AID - 10.1101/2021.11.30.21266810 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.30.21266810 4099 - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21266810.short 4100 - http://medrxiv.org/content/early/2021/12/02/2021.11.30.21266810.full AB - Background Convalescent plasma (CP) for hospitalized patients with COVID-19 has not demonstrated clear benefits. However, data on outpatients with early symptoms are scarce. We aimed to assess whether treatment with CP administered during the first 7 days of symptoms reduced the disease progression or risk of hospitalization of outpatients.Methods Two double-blind randomized trials (NCT04621123, NCT04589949) were merged with data pooling starting when <20% of their predefined sample size had been recruited. A Bayesian adaptive individual patient data meta-analysis was implemented. Analyses were done with Bayesian proportional odds and logistic models, where odds ratios (OR)<1.0 indicate a favorable outcome for CP. Fourteen study sites across the Netherlands and Catalonia in Spain participated in the trial. The two studies included outpatients aged ≥50 years and diagnosed with COVID-19 and symptomatic for ≤7days. The intervention consisted of one unit (200-300mL) of CP with a predefined minimum level of antibodies. The two primary endpoints were (a) a 5-point disease severity scale (fully recovered by day 7 or not, hospital or ICU admission and death) and (b) a composite of hospitalization or death.Results Of 797 patients included, 390 received CP and 392 placebo. At baseline, they had a median age of 58 years, 1 comorbidity, symptoms for 5 days and 93% tested negative for SARS-CoV-2 S-protein IgG antibodies. Seventy-four patients were hospitalized, 6 required mechanical ventilation and 3 died. The OR of CP for an improved disease severity scale was 0.936 (credible interval (CI) 0.667-1.311). The OR for hospitalization or death was 0.919 (CI 0.592-1.416). The effect of CP on hospital admission or death was largest in patients with ≤5 days of symptoms (OR 0.658, 95% CI 0.394-1.085). CP did not decrease the time to full symptom resolution (p=0.62).Conclusion Treatment with CP of outpatients in the first 7 days of symptoms did not improve the outcome of COVID-19. The possible beneficial effect in patients with ≤5 days of symptoms requires further study.Registration NCT04621123 and NCT04589949 on https://www.clinicaltrials.govFunding source ZONMW, the Netherlands, grant number 10430062010001.SUPPORT-E, grant number 101015756YoMeCorono, www.tomecorono.comThe Fight AIDS and Infectious Diseases Foundation with funding from the pharmaceutical company Grifols S.ACompeting Interest StatementThe authors have declared no competing interest.Clinical TrialThe COnV-ert study (NCT04621123) and the CoV-Early study (NCT04589949)Funding StatementThis study was funded by: ZONMW, the Netherlands, grant number 10430062010001. SUPPORT‐E, grant number 101015756 YoMeCorono, www.tomecorono.com The Fight AIDS and Infectious Diseases Foundation with funding from the pharmaceutical company Grifols S.A Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COnV-ert study received approval from the Institutional Review Board of the Hospital Germans Trias I Pujol (reference PI 20-313) and the CoV-Early study received approval from the Institutional Review Board of the Erasmus Medical Centre Rotterdam (reference MEC-2020-0682).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors